Dysregulated lipid metabolism links NAFLD to cardiovascular disease.
Dysregulated lipid metabolism links NAFLD to cardiovascular disease.
复制标题
DOI：
10.1016/j.molmet.2020.101092
复制
发表时间：
2020-12
影响因子：
8.1
通讯作者：
Staels B
中科院分区：
文献类型：
--
作者：
Deprince A;Haas JT;Staels B
非酒精性脂肪肝（NAFLD）正在迅速成为一个全球性的健康问题。心血管疾病（CVD）是NAFLD患者死亡的最常见原因。NAFLD和CVD有几个共同的风险因素，包括肥胖、胰岛素抵抗和2型糖尿病（T2 D）。在NAFLD患者中经常观察到动脉粥样硬化性血脂异常，其特征在于血浆高胆固醇血症、小而密的低密度脂蛋白（LDL）颗粒增加和高密度脂蛋白胆固醇（HDL-C）水平降低。在这篇综述中，我们强调了最近的流行病学研究评估NAFLD和CVD风险之间的联系。我们进一步关注最近NAFLD和脂蛋白代谢改变之间联系的机制见解。我们还讨论了目前NAFLD的治疗策略及其对NAFLD相关CVD风险的潜在影响。肝脏脂质和脂蛋白代谢的改变是NAFLD患者CVD风险增加的主要促成因素，许多正在开发的有前景的NASH疗法也在临床试验中改善血脂异常。
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a global health problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD patients. NAFLD and CVD share several common risk factors including obesity, insulin resistance, and type 2 diabetes (T2D). Atherogenic dyslipidemia, characterized by plasma hypertriglyceridemia, increased small dense low-density lipoprotein (LDL) particles, and decreased high-density lipoprotein cholesterol (HDL-C) levels, is often observed in NAFLD patients. In this review, we highlight recent epidemiological studies evaluating the link between NAFLD and CVD risk. We further focus on recent mechanistic insights into the links between NAFLD and altered lipoprotein metabolism. We also discuss current therapeutic strategies for NAFLD and their potential impact on NAFLD-associated CVD risk. Alterations in hepatic lipid and lipoprotein metabolism are major contributing factors to the increased CVD risk in NAFLD patients, and many promising NASH therapies in development also improve dyslipidemia in clinical trials.
登录
查看更多内容
血脂正常的非肥胖中国人群甘油三酯与高密度脂蛋白胆固醇比值与非酒精性脂肪肝的相关性：一项回顾性队列研究
影响因子：
4.5
作者：
Chen, Zekai;Qi, Hailun;Chen, Youren
通讯作者：
Chen, Youren
影响因子：
29.4
作者：
Chalasani N;Guo X;Loomba R;Goodarzi MO;Haritunians T;Kwon S;Cui J;Taylor KD;Wilson L;Cummings OW;Chen YD;Rotter JI;Nonalcoholic Steatohepatitis Clinical Research Network
通讯作者：
Nonalcoholic Steatohepatitis Clinical Research Network
影响因子：
5.1
作者：
Brouwers, Martijn C. G. J.;Simons, Nynke;Isaacs, Aaron
通讯作者：
Isaacs, Aaron
影响因子：
1.6
作者：
Abdelbasset, Walid Kamal;Tantawy, Sayed A.;Soliman, Gaber S.
通讯作者：
Soliman, Gaber S.
影响因子：
16.6
作者：
Bricambert J;Alves-Guerra MC;Esteves P;Prip-Buus C;Bertrand-Michel J;Guillou H;Chang CJ;Vander Wal MN;Canonne-Hergaux F;Mathurin P;Raverdy V;Pattou F;Girard J;Postic C;Dentin R
通讯作者：
Dentin R